On Thursday, Navient Corp (NASDAQ:NAVI)’s shares declined -1.46% to $18.56.
Navient Corp (NAVI) the nation’s leading loan administration, servicing and asset recovery company, has declared that Navient Foundation, the company-sponsored philanthropic organization, awarded a $22,000 grant to Luzerne County Head Start, a United Way agency dedicated to enhancing the quality of life for low-income children and their families.
Luzerne County Head Start offers multiple programs and services for children, counting preschool centers, an Early Head Start program for children up to age three, and children with disabilities.
Navient Corporation provides financial products and services in the United States. The company operates in four segments: FFELP Loans, Private Education Loans, Business Services, and Other. It provides federal family education loan program (FFELP) loans and servicing for FFELP loan portfolio; and servicing and asset recovery services for loans on behalf of guarantors of FFELP loans, guaranty agencies, higher education institutions, the United States Department of Education, and other federal clients, in addition to states, courts, and municipalities.
The Medicines Company (NASDAQ:MDCO)’s shares gained 2.43% to $30.34.
The Medicines Company (MDCO) declared the approval of KENGREAL™ (cangrelor) by the U.S. Food and Drug Administration (FDA) as an adjunctive therapy to percutaneous coronary intervention (PCI) for reducing periprocedural thrombotic events in patients who have not been treated with a P2Y12 inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor (GPI).
The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, in addition to acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases.
At the end of Thursday’s trade, TASER International, Inc. (NASDAQ:TASR)‘s shares surged 0.12% to $33.82.
TASER International, Inc. (TASR) on Thursday announced a large order of its Axon body-worn video cameras and Evidence.com back-end digital evidence management system. 400 of the mobile cameras will ship to the Dallas Police Department in Q2 of this year, with an additional 600 to be sent over the next three years.
Among the 20 other departments having ordered the body cameras this quarter are law enforcement agencies from Alameda, California to Portsmouth, Virginia. Police departments in 25 of America’s largest cities, including Chicago, Los Angeles, and Washington D.C. have already deployed TASER’s Axon Flex and Body cameras and implemented the Evidence.com system.
Shares of Taser were up more than 2.7 percent at $35.60 Thursday morning.
TASER describes the cameras as “small, yet highly visible.” They can be attached to hats, sunglasses, or shirt collars and capture full-color video from the point of view of the officer. The video is automatically uploaded to Evidence.com, a cloud-based storage database.
TASER International, Inc. develops, manufactures, and sells conducted electrical weapons (CEWs) worldwide. It operates through two segments, TASER Weapons and AXON. The companys CEW products transmit electrical pulses along the wires and into the body affecting the sensory and motor functions of the peripheral nervous system. It offers three hand-held CEW product lines, counting TASER X26P and TASER X2, which integrates with EVIDENCE.com; and TASER X26. The company also offers consumer products comprising TASER C2 CEW; smart cartridges, which communicate with the fire control system; standard cartridges that are used in CEW systems for warm and cold climates, training scenarios, and tactical situations; and training cartridges, which allow law enforcement, military, and corrections trainers to use the cartridge during training, in addition to other accessories, such as standard replacement and modified batteries.
Heron Therapeutics Inc (NASDAQ:HRTX), ended its Thursday’s trading session with -0.81% loss, and closed at $29.39.
Xenia Hotels & Resorts Inc (XHR) declared that its Board of Directors has authorized a cash dividend of $0.23 per share of the Company’s common stock for the second quarter of 2015. The dividend will be paid on July 15, 2015 to all holders of record of the Company’s common stock as of the close of business on June 30, 2015.
The Board of Directors also authorized a cash dividend for a partial six month period of $61.11 per share of the Company’s 12.5% Series A Cumulative Non-Voting Preferred Stock for the first six months of 2015. The dividend will be paid on June 30, 2015 to all holders of record of the preferred stock as of the close of business on June 15, 2015.
Xenia Hotels & Resorts, Inc. operates as a self-advised and self-administered REIT that invests in full service hotels in the United States. As of December 31, 2014, it owned 46 hotels comprising 12,636 rooms across 19 states and the District of Columbia. The company is based in Orlando, Florida.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
